Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

The Quick Take
Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 market leader in new patient starts and total active patients for both...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
BROCO ENERGY AWARDED TWO FIVE-YEAR MASSACHUSETTS STATEWIDE FUEL CONTRACTS
Statewide awards include renewable diesel, biodiesel, heating oil and eligible liquid biofuel for public entities across the Commonwealth. BOSTON, Nov. 4, 2026…
Business
Goldcom earnings missed by $0.88, revenue fell short of estimates
Business
Olin extends receivables purchase agreement termination date to July 2028
Business
